BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15363464)

  • 21. FDG-PET in the clinical management of Hodgkin lymphoma.
    Hutchings M; Eigtved AI; Specht L
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of PET in lymphoma.
    Jhanwar YS; Straus DJ
    J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of FDG-PET/CT in the management of lymphoma.
    Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
    Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
    Kostakoglu L; Evens AM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New developments in staging and follow-up of patients with Hodgkin's lymphoma.
    van Spronsen DJ; Veldhuis GJ
    Neth J Med; 2003 Sep; 61(9):278-84. PubMed ID: 14692440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PET and PET/CT in management of the lymphomas.
    Podoloff DA; Macapinlac HA
    Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of early PET in the management of diffuse large B-cell lymphoma.
    Michallet AS; Trotman J; Tychyj-Pinel C
    Curr Opin Oncol; 2010 Sep; 22(5):414-8. PubMed ID: 20683268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
    Adams HJ; Kwee TC
    Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of PET in lymphoma.
    Gallamini A; Borra A
    Curr Treat Options Oncol; 2014 Jun; 15(2):248-61. PubMed ID: 24619427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk- and response-adapted strategies for the management of Hodgkin lymphoma.
    Remer M; Johnson PW
    Chin Clin Oncol; 2015 Mar; 4(1):13. PubMed ID: 25841720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early interim PET scan in Hodgkin lymphoma: where do we stand?
    Gallamini A; Hutchings M; Avigdor A; Polliack A
    Leuk Lymphoma; 2008 Apr; 49(4):659-62. PubMed ID: 18398732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ¹⁸F-FDG PET and PET/CT patient preparation: a review of the literature.
    Surasi DS; Bhambhvani P; Baldwin JA; Almodovar SE; O'Malley JP
    J Nucl Med Technol; 2014 Mar; 42(1):5-13. PubMed ID: 24503347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography.
    Hutchings M
    Cancer J; 2018; 24(5):215-222. PubMed ID: 30247256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized treatment of lymphoma: promise and reality.
    Ramsdale E; van Besien K; Smith SM
    Semin Oncol; 2011 Apr; 38(2):225-35. PubMed ID: 21421112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When should FDG-PET be used in the modern management of lymphoma?
    Barrington SF; Mikhaeel NG
    Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
    Evens AM; Kostakoglu L
    Blood; 2014 Nov; 124(23):3356-64. PubMed ID: 25428223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.